Skip to main content
FinSpry Logo
FinSpry
REGN logo
REGN
(NASDAQ)
Regeneron Pharmaceuticals, Inc.
$611.34-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Regeneron Pharmaceuticals (REGN) Stock Price & Financial Analysis

Regeneron Pharmaceuticals Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$632.09 - $640.82
52-Week High$821.11
52-Week Low$485.00
Open$632.26
Volume975.37K
Average Volume (3M)1.08M
Market Cap67.71B
Shares Outstanding107.70M
P/E Ratio (TTM)15.31
Forward P/E15.74
Price to Sales (P/S)4.54
Price to Book (P/B)2.15
EV/EBITDA14.68
Revenue (TTM)14.92B
Net Income (TTM)4.42B
Free Cash Flow (TTM)4.02B
EPS (TTM)$41.05
Profit Margin29.65%
Operating Margin25.13%
Return on Equity (ROE)14.08%
Debt to Equity0.06
50-Day MA$707.12
200-Day MA$695.89
52-Week Change31.54%
Annual Dividend$3.64
Dividend Yield0.57%
Payout Ratio8.87%
Last Dividend Ex-DateMay 20, 2026

Frequently Asked Questions About Regeneron Pharmaceuticals

What is the current stock price for REGN?

As of the latest trading session, REGN stock trades at $635.45. The 52-week range is $485.00–$821.11, with a day range of $632.09–$640.82.

What is the P/E ratio for REGN?

Regeneron Pharmaceuticals's trailing P/E ratio is 15.3, meaning investors pay $15.3 for every $1 of annual earnings. The forward P/E is 15.7, reflecting analyst expectations for future earnings. Regeneron Pharmaceuticals operates in the Healthcare sector.

Does REGN pay dividends?

Yes, Regeneron Pharmaceuticals pays a 0.57% annual dividend yield ($3.64 per share). The payout ratio is 8.9%. The last ex-dividend date was 2026-05-20.

What do analysts recommend for REGN?

Based on 6 analysts, the consensus for REGN is Strong Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of REGN?

Regeneron Pharmaceuticals's market capitalization is $68.44B, classifying it as a large-cap company. Regeneron Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.